肝毒性を示す医薬品の代謝活性化機構の解析とそれに基づいた創薬戦略

DOI Web Site Web Site PubMed 被引用文献1件 参考文献13件 オープンアクセス

書誌事項

タイトル別名
  • Strategic Drug Design to Avoid the Metabolic Activation of Hepatotoxic Drugs
  • Symposium Review 肝毒性を示す医薬品の代謝活性化機構の解析とそれに基づいた創薬戦略
  • Symposium Review カン ドクセイ オ シメス イヤクヒン ノ タイシャ カッセイカ キコウ ノ カイセキ ト ソレニ モトズイタ ソウヤク センリャク

この論文をさがす

抄録

 Adverse reactions are one of the most important issues in drug development, as well as in the therapeutic usage of drugs during the post-approval stage. Specifically, idiosyncratic adverse drug reactions (IDR) occur in only a small group of patients who are treated with certain drugs, and are unpredictable. It is widely accepted that drug-induced IDR is often associated with CYP-mediated bioactivation. Benzbromarone (BBR) is effective in the treatment of hyperuricemia, and has been used as an effective drug in Japan for a long time. However, BBR has been associated with hepatotoxicity, including fatal liver injury. We identified 2,6-dibromohydroquinone (DBH) and mono-debrominated catechol (CAT) as novel metabolites of BBR in human and rat liver microsomal systems, by comparison with chemically synthesized authentic compounds via ipso-substitution, which we previously discovered to be a unique metabolic reaction of substituted phenols by CYP. Furthermore, CAT, DBH and the oxidized form of DBH (DBBQ) were highly cytotoxic in human hepatocellular carcinoma cells, compared with BBR. We consider that the formation of these metabolites from BBR is linked to the mechanism involved in BBR-induced hepatotoxicity because catechols, hydroquinones, and their oxidized forms are known to be toxic.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 137 (3), 249-255, 2017-03-01

    公益社団法人 日本薬学会

被引用文献 (1)*注記

もっと見る

参考文献 (13)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ